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Abstract
Laboratory-based HIV tests for recent infection (TRIs), which primarily measure a specific serological biomarker(s) that
distinguishes recent from long-term HIV infection, have facilitated the estimation of population-based incidence. Dried
blood spots (DBS) on filter paper are an attractive sample source for HIV surveillance, given the simplified and cost-effective
methods of specimen collection, storage, and shipment. Here, we evaluated the use of DBS in conjunction with an in-house
multiplex TRI, the HIV-1-specific Bio-Plex assay, which measures direct antibody binding and avidity to multiple HIV-1
analytes. The assay performance was comparable between matched plasma and DBS samples from HIV-1 infected
individuals obtained from diverse sources. The coefficients of variation, comparing the median antibody reactivity for each
analyte between plasma and DBS, ranged from 2.78% to 9.40% and the correlation coefficients between the two sample
types ranged from 0.89 to 0.97, depending on the analyte. The correlation in antibody reactivity between laboratory and
site-prepared DBS for each analyte ranged from 0.87 to 0.98 and from 0.90 to 0.97 between site-prepared DBS and plasma.
The correlation in assay measures between plasma and DBS indicate that the sample types can be used interchangeably
with the Bio-Plex format, without negatively impacting the misclassification rate of the assay.
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Introduction
Since the first AIDS cases were identified more than 30 years
ago [1], significant advances have been made towards diagnosing
HIV infection, developing anti-retroviral therapy (ART) regimens,
and implementing transmission prevention measures. Despite this
ever-evolving progress, an HIV vaccine remains elusive and an
estimated 34 million people globally are living with HIV infection
[1]. HIV surveillance methods have been instrumental in
monitoring the status of the epidemic; however, surveillance has
primarily focused on the prevalence of HIV in the population.
Estimates of HIV incidence are crucial for understanding the
dynamics of the epidemic and assessing the efficacy of prevention
measures [2]; however, recent acquisition of HIV infection is
difficult to extrapolate from standard diagnostic test results.
In 1998, a ground-breaking study by Janssen et al. described the
development of a detuned or less-sensitive serologic assay for
distinguishing recent from long-term HIV-1 infection, which
allowed for incidence estimation from cross-sectional patient
samples. Several serology-based laboratory tests for recent
infection (TRI) have been developed that measure a specific
biomarker, primarily HIV-1-specific antibody [3,4], avidity [5–9],
or both [10,11], that evolves in a predictable pattern from early to
late infection. To date, two TRIs have been commercialized for
HIV-1 surveillance purposes, the BED-CEIA (Sedia Biosciences
Corp., Portland, OR; Calypte Biomedical Corp., Portland, OR)
and HIV-1 Limiting Antigen (LAg)-Avidity EIA (Sedia Biosciences
Corp.; Maxim Biomedical, Inc., Rockville, MD). The BED assay
has been used to calculate HIV-1 incidence estimates in the
United States and worldwide. [12–15].
Given that the majority of current TRI approaches are
serology-based, the most commonly used sample type for
incidence testing is plasma and/or serum. Although HIV-1-
specific antibodies are stable in plasma and serum, sample
collection is somewhat limited due to processing and storage
requirements. Dried blood spots (DBS) have been used extensively
for HIV testing and surveillance, as they can be prepared from a
finger stick, do not require centrifugation, and can be shipped at
room temperature. HIV biomarkers remain stable on the DBS
filter paper; with minimal risk of infectivity once the sample is fully
dried [16]. Applications for DBS are numerous, including HIV-1-
specific antibody testing, genotyping, viral nucleic acid amplifica-
tion [17,18], and drug resistance testing [19]. Furthermore, the use
of DBS as a sample source for HIV-1 incidence estimation has
been reported [20–22]. Protocol adaptations for DBS are currently
supplied by the manufacturer for use with both the BED (Sedia
Biosciences Corp.; Calypte Biomedical Corp.) and LAg assays
(Maxim Biomedical Inc.). Collection of whole blood on DBS filter
paper increases the applicability of laboratory-based TRIs, given
that sample collection is suitable for multiple settings, including
resource limited sites where the epidemic is often concentrated.
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To improve upon the accuracy of TRIs for estimating
incidence, it has been demonstrated that multiassay algorithms
(MAAs), combining one or more TRIs with clinical data, yield
improved incidence estimates and reduced false-recent rates as
compared to each individual test [23–26]. Recently, we described
the development of an in-house HIV-specific multiplex assay,
based on the Bio-Plex format, which measures HIV-specific
antibody levels and avidity to multiple analytes [10]. Improved
incidence estimates have been demonstrated using multi-analyte
algorithms based on three or more assay measures obtained from
the multiplex format [27]. Thus far, all assay development for the
HIV-1-specific Bio-Plex assay has been performed with plasma
samples. In the current study, we evaluate the use of DBS as an
additional sample source for determining recent infection with the
multiplex assay. We compared assay performance with matched
plasma and DBS samples from HIV-1 infected individuals
obtained from diverse sources.
Materials and Methods
Study cohorts
Longitudinal seroconversion panels were obtained through the
Seroconversion Incidence Panel Project (SIPP) in collaboration
with SeraCare Life Sciences, Inc. (Milford, MA). The objective of
the study was to identify recent HIV-1 seroconverters, as defined
as having acquired HIV within the past 90 days. Donors were
enrolled at plasma donation centers and HIV testing and/or
clinical sites within the United States. Study participants were at
least 18 years of age and met either of the following criteria: (1)
detectable viral RNA with a negative or indeterminate antibody
test result or (2) positive HIV antibody test with a documented
negative test result within the past 90 days. Based on these criteria,
20 HIV-1 seroconverters were identified and enrolled for follow-
up blood collection. Whole blood collection in EDTA vacutainers
was initiated within 120 days from the date of the last negative or
indeterminate HIV antibody test result. Blood samples were
collected monthly for the first six months, followed by every three
months for up to 15 months. Follow-up blood collections were
continued after 15 months for most study participants (total follow-
up time ranged from 189 to 1130 days). Twelve of the study
participants had documented antiretroviral (ARV) use during the
sample collection period. Cross-sectional samples from HIV-1
infected individuals with chronic or long-term infection were also
collected. The last 2–3 samples collected from each of the
seroconverters were included in the current study, along with 6 of
the cross-sectional, long-term specimens (49 specimens/26 partic-
ipants).
Cross-sectional samples from HIV-1 infected men who have sex
with men (MSM) were obtained through CDC’s National
Behavioral and Surveillance (NHBS) system, as part of the
MSM3 cycle. HIV-1 infected MSM were identified through
routine testing in five US cities (Baltimore, Denver, Los Angeles,
Miami, and Washington DC), as described in detail [28]. Briefly,
whole blood in EDTA was collected from individuals with an
initial HIV-1 rapid test result or self-reported HIV positives. All
participants with a preliminary positive test result were confirmed
HIV positive through site-specific HIV-1 diagnostic testing
algorithms. Last negative and first positive HIV-1 antibody test
results are not available for these participants. For the purposes of
this study, 51 specimens were randomly selected from the NHBS
cohort for inclusion in the analyses. All SIPP and NHBS
specimens are from individuals with subtype B HIV-1 infections.
Lastly, cross-sectional specimens were obtained from HIV-1
infected donors from Cameroonian blood banks, as described
elsewhere [19,29]. Whole blood was collected as part of a
surveillance study to characterize global HIV subtype diversity. A
total of 52 Cameroonian specimens were included in the current
study and determined to be from diverse, non-B subtype HIV-1
infections, as described [19,29]. Recent/long-term HIV-1 infec-
tion status is unknown for the Cameroonian cohort, since last
negative and first positive test results are not available for these
participants. All samples were unlinked from personal identifiers
and determined not to be human subjects research by the Centers
for Disease Control and Prevention.
Sample preparation
For the SIPP and NHBS cohorts, whole blood was shipped to
the CDC at ambient temperature, within 48 hours of collection.
DBS were made from whole blood by aliquoting 50 ml blood per
spot on Whatman 903 Protein Saver cards (GE Healthcare Life
Sciences, Piscataway, NJ). Each card was dried overnight at room
temperature and packaged individually in Bitran bags (Fisher
Scientific Company, Pittsburgh, PA) with silica gel desiccant bags
and humidity indicating cards (McMaster-Carr Supply Co,
Atlanta, GA). The DBS were stored at -20uC until ready for
use. Matched plasma samples were prepared from the whole blood
and stored at 280uC prior to testing. In addition to the CDC-
prepared specimens, DBS were also prepared at the time of
collection at one of the NHBS testing sites. Of the 51 NHBS
participants included in this study, 14 had matched CDC and site-
prepared DBS.
Sample collection and storage for the Cameroonian samples
have been described previously [19,29].
DBS elution
A standard paper punch was used to obtain a 6.3 mm
(diameter) blood spot from the DBS cards. Each blood spot was
transferred to one well in a flat-bottom 96-well plate with 250 ml
pre-incubation buffer (PBS with 1% BSA, 0.5% polyvinylalcohol
(Sigma-Aldrich, St. Louis, MO), and 0.8% polyvinylpyrrolidone
(Sigma-Aldrich)) [10] per well. The plate containing the blood
spots was incubated overnight at room temperature to allow
sample elution. The eluted sample was added directly into the Bio-
Plex assay plate (50 ml sample/well).
HIV-specific Bio-Plex assay
The HIV-1-specific Bio-Plex assay was performed on the
matched plasma and DBS samples, as described [10,27]. Magnetic
COOH beads (Bio-Rad Laboratories, Hercules, CA) were coupled
to the recombinant HIV-1 proteins, gp120, gp160, and gp41
(Immunodiagnostics, Inc., Woburn, MA). The recombinant
proteins were derived from subtype B strains HIV-1 IIIB (gp120
and gp160) and MN (gp41). All plasma/eluted DBS samples were
tested in duplicate under both treatment conditions, with and
without diethylamine (DEA), and normalized mean fluorescent
intensity (MFI) values and avidity indices were calculated as
previously described [10,27]. The normalized MFI value for gp41
was not included in the study analyses given that the analyte does
not elicit sufficient separation in assay reactivity between recent
and long-term specimens [10] and, therefore, is not useful for
estimating HIV-1 incidence. A representative incident and
prevalent sample was included in each run to assess inter-run
variation. The standards were obtained from an HIV-1 Inci-
dence/Prevalence performance panel (SeraCare Life Sciences,
Milford, MA).
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Data analysis
To establish a baseline level of variation associated with the
assay platform, intra-assay variation was assessed by calculating
the coefficient of variation (CV) for the MFI values of each sample
replicate. CVs were also calculated for the incident/prevalent
standards included in each run. To evaluate variation associated
with sample type, the CV comparing HIV-specific IgG antibody
reactivity of plasma versus DBS was calculated for each analyte.
The relationship between antibody reactivity of the plasma and
DBS was also determined using Spearman’s rank correlation
coefficient.
Determination of recent infection
To determine whether sample type affects the ability of the Bio-
Plex assay to discriminate between recent and long-term HIV
infection, cutoff values were determined for each analyte. In the
absence of finalized cutoff values for the overall assay, the range of
reactivity for known recent and long-term samples was determined
using an HIV-1 Incidence/Prevalence Performance Panel (Ser-
aCare Life Sciences). Given the minimal to no overlap between
the reactivity of the recent and long-term panel members, the top
end of the 95% confidence interval for the reactivity of the recent
samples was selected as a cutoff for the purposes of the current
analyses. For the study specimens, recent infection was defined as
any value below the analyte-specific cutoff.
Results
Comparison of Plasma and DBS
Intra-assay reproducibility was relatively high for both plasma
and DBS samples for all analytes (Table 1). The median
coefficient of variation (CV) of the sample replicates for each
analyte ranged from 0.84 to 1.96 for plasma and 0.66 to 1.49 for
DBS. A comparison of the normalized MFI values (n) and avidity
index (a) for both sample types is shown in Figure 1. The variation
in antibody reactivity between plasma and DBS was similar to the
intra-assay variation, as measured by the CVs of the standards
included in each assay plate (Table 2). The correlation coefficient
(r) between assay values for plasma and DBS ranged from 0.89 to
0.97 for all cohorts. When analyzed separately, the avidity
measures exhibited highly reproducible results for all cohorts
(r$0.9), while the correlation in normalized values was slightly
more variable between cohorts (r$0.8).
Figure 1. Correlation between plasma and DBS. The normalized MFI values (n) and avidity index (a) for plasma versus DBS were compared for
all specimens. The solid line represents the linear trend line for all data points.
doi:10.1371/journal.pone.0107153.g001
Table 1. Intra-assay variability.






aCalculated based on MFI values of intra-assay sample replicates.
doi:10.1371/journal.pone.0107153.t001
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Comparison of site and CDC specimens
The correlation in assay reactivity between CDC and site-
prepared DBS was highly reproducible, with r values ranging from
0.87 to 0.98 for all analytes (Table 3). Similarly, the site-prepared
DBS yielded assay values consistent with the plasma specimens
(r = 0.90 to 0.97). A comparison of the normalized MFI values and
avidity index for the CDC versus site-prepared specimens is shown
in Figure 2.
Determination of recent infection
Cutoff values for each analyte, chosen based on the assay
reactivity of the performance panel, are listed in Table 4. For the
study cohorts, all specimens with assay values below the analyte-
specific cutoff were considered recent. The numbers of recent
infections for plasma and DBS samples are shown in Table 4. For
most analytes, the number of specimens determined to be recent
were similar for both sample types. For plasma and DBS, the
number of recent infections were identical for gp120-a and gp160-
a. Recent infections differed by one for gp120-n and two for
gp41-a. The largest discrepancy was for gp160-n, in which the
recent infections differed by five samples.
Discussion
In previous studies, we described the development and
performance characteristics of an in-house HIV-1-specific Bio-
Plex assay for determination of recent HIV-1 infection with
plasma specimens [10,27,30]. Here, we evaluate the use of DBS
eluates as an additional sample source for the customized Bio-Plex
assay. The detection of HIV-1 antibodies from DBS using the
Luminex technology (Luminex Corporation, Austin, TX) has been
demonstrated for diagnostic purposes [31]; however, tests for
recent infection require unique considerations given that the time
of infection must be estimated with a fair degree of accuracy.
Furthermore, our assay approach incorporates measurement of
both total HIV-1-specific antibody binding and avidity; therefore,
it is crucial to demonstrate that neither measure is significantly
altered by sample type. Overall, comparable performance was
demonstrated between matched plasma and DBS samples for both
direct antibody binding and avidity measures. The consistency
between sample types suggests that plasma and DBS can be used
interchangeably with the Bio-Plex format, without negatively
impacting the misclassification rate of the assay.
Given that most assays are subject to some degree of innate
variation, it is important to characterize the baseline intra- and
inter-assay variation prior to assessing potential differences in
sample types. Specimen replicates yielded highly reproducible
assay measures, irrespective of sample type. These findings were
consistent with a previous study demonstrating performance of our
in-house HIV-1 Bio-Plex assay versus a prototype kit, using plasma
specimens [30]. Although samples were plated in duplicate for the
purposes of the assay evaluation, the high degree of reproducibility
supports the use of a single well for specimen testing, which
improves the cost effectiveness of the assay. For all samples tested,
the assay measures were remarkably similar between plasma and
DBS for most analytes and any differences between the sample
types could not be discerned from the innate variation associated
with assay.
Specimens from three separate cohorts were evaluated in this
study to assess potential inconsistencies due to site-specific sample
collection or storage methods. Not surprisingly, the avidity
measures were the most consistent between the cohorts. As
observed in previous studies, avidity measures tend to be less
affected by slight alterations in the assay or sample, given that
avidity index is calculated relative to a control included within the
same assay plate [10,27,30]. The correlation in normalized values
Table 2. Correlation in antibody reactivity between plasma and DBS.
Analyte CV% Correlation Coefficient (r)
Inter-assay standardsa Plasma vs. DBSb SIPP (n = 49) NHBS (n = 51) Cameroon (n = 52) All (n = 152)
gp120-n 11.14 9.40 1.00 0.90 0.83 0.89
gp160-n 6.71 3.81 0.99 0.79 0.95 0.97
gp120-a 7.00 4.28 0.99 0.96 0.94 0.96
gp160-a 7.33 2.78 0.99 0.97 0.96 0.97
gp41-a 3.99 5.09 0.99 0.93 0.89 0.95
aInter-assay variation, as measured by repeat testing of know Incident/Prevalent controls. CV is representative of median values for standards.
bMedian value for all samples, comparing plasma and DBS values.
doi:10.1371/journal.pone.0107153.t002
Table 3. Correlation with site-prepared DBS.
Analyte Correlation Coefficient (r)
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between plasma and DBS tended to vary slightly between the
cohorts. The SIPP cohort yielded highly consistent results for all
analytes, with r values of 0.99 or 1. This may be the result of well-
controlled sample and data collection, along with the fact that the
specimens included in the current study were collected from a
single site and freeze-thaw cycles were minimal for the plasma
specimens. The NHBS cohort also exhibited high correlation
between sample types; however, a lower r value of 0.79 for gp160-
n was skewed by a single outlier. Unfortunately, limited sample
volume for this particular study participant prevented repeat
testing. For this particular cohort, site-prepared DBS were also
available for some of the study participants. We did not observe
any differences in reactivity between the site and CDC-prepared
samples, which demonstrates that samples can be collected at field
sites, shipped, and stored for later testing. The Cameroon
specimens were the oldest of the three cohorts, as they were
collected and stored 10–15 years ago and the DBS had been
freeze-thawed multiple times for previous testing. Additionally, the
Cameroon cohort exhibited a large degree of HIV-1 subtype
diversity. Despite the age of the specimens and subtype diversity,
the correlation between sample types was high for all analytes. It is
important to note that any differences in reactivity between sample
types might be exaggerated given the small sample numbers
included in current study.
One of the most important considerations for a TRI is whether
the recent/long-term classification is impacted by the use of DBS,
Table 4. Number of recent infections.
Analyte Cutoff Value # Recent
a
Plasma DBS
gp120-n 2.3 29 30
gp160-n 2.5 56 61
gp120-a 11.6 26 26
gp160-a 26.8 11 11
gp41-a 24.1 24 26
aNumber of samples classified as recent out of 152 total specimens.
doi:10.1371/journal.pone.0107153.t004
Figure 2. CDC versus field DBS. The normalized MFI values and avidity index were compared for CDC versus field-prepared DBS. The solid lines
represent the linear trend lines.
doi:10.1371/journal.pone.0107153.g002
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thereby affecting incidence estimates. Since ‘‘true’’ recent/long-
term status is not known for all of the samples included in this
study, we compared the number of recent infections as determined
by the assay values for plasma versus DBS. This evaluation was
done strictly for demonstrative purposes, as finalized cutoffs have
yet to be determined for the assay. Although demonstrated with a
relatively small sample set, the number of specimens classified as
recent were similar (differences #2) between plasma and DBS for
all analytes except gp160-n. The number of specimens classified as
recent differed between the analytes, given that each analyte has a
distinct mean duration of recency (MDR) and, therefore, the
determination of recent infection is analyte-specific [27]. Differ-
ences in classification between sample types were associated with
specimens that elicited assay values close to the analyte cutoff. It is
likely that misclassifications due to values close to the cutoff will
decrease when the analyte measures are used in an algorithm to
determine recent infection. The largest difference in recent
classifications was observed for gp160-n, which is not surprising
given the narrow range of reactivity between recent and long-term
specimen. Given the high MFI values elicited from the gp160 bead
set, titration of the gp160 protein on the beads can be performed
to improve the measurable distinction between recent and long-
term specimens (data not shown). Although each analyte was
evaluated separately in the current study, an algorithm of analyte
measures employing a common cutoff and MDR will be used to
determine recent infection, as described previously [27]. The
optimal algorithms for the current assay will be addressed in a
separate study.
Given that most TRI formats are laboratory-based, the use of
DBS as an additional sample source is highly valuable since
samples can be collected in resource-limited settings and shipped
for later testing. We demonstrate stable reactivity of antibodies
from DBS, even after specimens have been stored for several years.
The modification to utilize DBS for the HIV-1 Bio-Plex assay
described here expands its utility as a TRI for estimating HIV
incidence.
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